Serentis starts recruiting into Ph II eczema drug trial

Serentis, a privately-owned UK biopharmaceutical company, has commenced patient recruitment in a Phase II trial for atopic dermatitis, a type of  eczema.

The Phase II, double-blind, vehicle-controlled study will determine the  efficacy, safety and tolerability of SRD441 in patients with AD.

The 28-day study in adults with mild-to-moderate AD is being conducted  in 12 sites across Europe and will measure acute efficacy as defined by  the Investigators' Global Assessment, a clinical endpoint commonly used  in AD trials. Results are expected later this year.